<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of rosacea</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of rosacea</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of rosacea</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa E Maier, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2324120"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rosacea is a chronic and relapsing inflammatory skin disorder that primarily involves the central face. Common clinical features include facial erythema, telangiectasias, and inflammatory papules or pustules. Many patients seek therapy due to concern over the effect of rosacea on physical appearance. As there is no cure for rosacea, treatment is focused on symptom suppression.</p><p>The management of rosacea will be discussed here. The pathogenesis and clinical features of rosacea are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2324127"><span class="h1">PATIENT ASSESSMENT</span><span class="headingEndMark"> — </span>Rosacea can manifest with a wide variety of cutaneous features. Examples include persistent centrofacial redness, phymatous skin changes (eg, rhinophyma), papules, pustules, flushing, telangiectases, burning or stinging sensations, edema, and skin dryness  (<a class="graphic graphic_picture graphicRef77020 graphicRef56083 graphicRef67890 graphicRef78747 graphicRef61822" href="/z/d/graphic/77020.html" rel="external">picture 1A-E</a>). Ocular involvement may also occur, manifesting with lid margin telangiectases, conjunctival injection, ocular irritation, or other signs and symptoms. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p>The classification of rosacea has evolved from a division into distinct subtypes (erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea) to a phenotype-based approach that views the various features of rosacea as manifestations of a continuous multivariate disease process. The approach to treatment is guided by the clinical features present in an individual patient. Given the common presence of multiple features, combination therapy may be necessary to achieve satisfactory control of disease [<a href="#rid1">1,2</a>]. (See <a class="local">'Facial redness, flushing, skin sensitivity, and skin dryness'</a> below and <a class="local">'Papules and pustules'</a> below and <a class="local">'Ocular manifestations'</a> below and <a class="local">'Phymatous skin changes'</a> below and  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Classification'</a>.)</p><p class="headingAnchor" id="H2324134"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions may be useful for the management of the cutaneous manifestations of rosacea. These include avoidance of triggers of flushing, gentle skin care, sun-protection, and the use of cosmetic products. </p><p class="headingAnchor" id="H2324141"><span class="h2">Avoidance of flushing</span><span class="headingEndMark"> — </span>Easy flushing is a common feature of rosacea. Flushing is a prominent and troubling symptom for some patients, and some authors have proposed that flushing may contribute to worsening of other features of rosacea, such as inflammatory papules, erythema, and skin sensitivity [<a href="#rid3">3-5</a>]. </p><p>Potential triggers for flushing include [<a href="#rid4">4,6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Extremes of temperature</p><p class="bulletIndent1"><span class="glyph">●</span>Sunlight</p><p class="bulletIndent1"><span class="glyph">●</span>Spicy foods</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol </p><p class="bulletIndent1"><span class="glyph">●</span>Exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Acute psychologic stressors</p><p class="bulletIndent1"><span class="glyph">●</span>Medications</p><p class="bulletIndent1"><span class="glyph">●</span>Menopausal hot flashes </p><p></p><p>Individual patients may also have unique triggers for flushing, and the degree of flushing in response to the above stimuli is variable. Thus, asking patients to keep a diary of flushing episodes and potential associated factors can be useful for identifying and avoiding pertinent triggers. In addition, practical measures to reduce flushing after encounters with stimuli, such as applying cool compresses and transferring to cool environments, may be helpful. </p><p>A variety of pharmacologic agents, including <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, beta-blockers, antidepressants, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and topical <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">oxymetazoline</a> have been used in attempts to reduce flushing [<a href="#rid9">9-16</a>]. However, data are limited on their efficacy in rosacea and no single therapy appears to be consistently effective. Moreover, the potential for drug-related adverse effects must be considered. (See  <a class="medical medical_review" href="/z/d/html/2782.html" rel="external">"Approach to flushing in adults", section on 'Treatment'</a>.)</p><p>Laser, intense pulsed light, and photodynamic therapy also have been used for patients with rosacea-related flushing, but data are limited on treatment effects [<a href="#rid17">17-20</a>]. </p><p class="headingAnchor" id="H2324148"><span class="h2">Skin care</span><span class="headingEndMark"> — </span>Patients with rosacea, particularly those with centrofacial erythema and telangiectases, can experience heightened sensitivity of facial skin characterized by difficulty tolerating topical cosmetics, skin care products, and topical medications [<a href="#rid21">21</a>]. In addition, rough, dry, or scaly facial skin is a common feature. </p><p>It is unclear whether subjective skin sensitivity and dryness result from abnormalities in skin barrier function that precede the development of rosacea, or whether they occur as a consequence of the inflammatory process [<a href="#rid22">22</a>]. Regardless, gentle skin care practices may help to reduce symptoms. Appropriate measures include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequent skin moisturization </strong>– Emollients help to repair and maintain cutaneous barrier function and may be useful in rosacea [<a href="#rid23">23,24</a>]. In a 15-day, split-face study of 20 patients with rosacea (manifesting as erythema, flushing, sensitive and dry skin, stinging, burning, and/or skin discomfort) treated with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel, concomitant application of a moisturizing cream twice daily was associated with a significant reduction in experimentally-induced symptoms of skin sensitivity [<a href="#rid24">24</a>]. Relatively greater reductions in scores of skin dryness, roughness, and discomfort were also detected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gentle skin cleansing </strong>– Despite their sensitive skin, patients should cleanse their faces at least once daily. Patients should be instructed to cleanse their skin gently with lukewarm water, to wash with their fingers, and to avoid harsh mechanical scrubbing [<a href="#rid21">21,25</a>]. Non-soap cleansers with synthetic detergents (eg, beauty bars, mild cleansing bars, many liquid facial cleansers) are usually better tolerated than traditional soaps. The latter are alkaline, which may raise the pH of the skin to abnormal levels and impair skin barrier function [<a href="#rid26">26</a>]. In contrast, synthetic detergent cleansers typically have a pH that more closely approximates the normal pH of the skin (skin pH = 4.0 to 6.5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of irritating topical products </strong>– Patients should avoid topical products that may irritate the skin, such as toners, astringents, and chemical exfoliating agents (eg, alpha hydroxy acids) [<a href="#rid25">25,26</a>]. Manual exfoliation with rough sponges or cloths also should be avoided. Skin care products in the form of foams, powders, or creams are generally better tolerated than alcohol-based gels and thin lotions [<a href="#rid25">25</a>]. In addition, cosmetics should be easy to remove to avoid the need for harsh cleansing [<a href="#rid25">25</a>]. </p><p></p><p class="headingAnchor" id="H2324155"><span class="h2">Sun protection</span><span class="headingEndMark"> — </span>The role of sun exposure in the pathogenesis of rosacea is uncertain. Flares of facial redness and flushing may be stimulated by exposure to radiant heat from the sun, and ultraviolet radiation may induce cutaneous changes that promote rosacea. </p><p>We routinely recommend daily application of a broad-spectrum sunscreen with a sun protection factor (SPF) of at least 30 and educate patients on mid-day sun avoidance and the use of sun-protective clothing. Sunscreens in the form of creams, lotions, or preparations that contain barrier protective silicones (eg, <a class="drug drug_general" data-topicid="129549" href="/z/d/drug information/129549.html" rel="external">dimethicone</a> or cyclomethicone) are preferred over those in an alcohol-based vehicle, which may be more likely to cause irritation [<a href="#rid27">27,28</a>]. </p><p class="headingAnchor" id="H2324162"><span class="h2">Cosmetic camouflage</span><span class="headingEndMark"> — </span>For patients who are bothered by facial erythema or telangiectasias, green-tinted foundation can help to camouflage these features. A flesh-colored facial foundation should be applied on top of the green-tinted foundation to achieve a color that matches the patient's complexion [<a href="#rid29">29</a>]. Light application of a green-tinted cosmetic facial powder can also be useful for camouflaging facial redness.</p><p class="headingAnchor" id="H1009797073"><span class="h1">FACIAL REDNESS, FLUSHING, SKIN SENSITIVITY, AND SKIN DRYNESS</span></p><p class="headingAnchor" id="H2324942"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>Nonpharmacologic measures may assist with reducing facial redness, flushing, skin sensitivity, and skin dryness, and are sufficient for the management of some patients with mild symptoms. When satisfactory improvement cannot be attained with these interventions, treatment with lasers, intense pulsed light, or pharmacologic agents is an option. The treatment of flushing is challenging; the management of this feature is discussed in greater detail elsewhere. (See <a class="local">'Avoidance of flushing'</a> above and  <a class="medical medical_review" href="/z/d/html/2782.html" rel="external">"Approach to flushing in adults", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2324949"><span class="h3">First-line interventions</span><span class="headingEndMark"> — </span>Behavioral changes can be beneficial. We educate all patients on the avoidance of triggers of flushing, proper use of sun protection, and gentle skin care [<a href="#rid3">3,27</a>]. (See <a class="local">'General measures'</a> above.)</p><p class="headingAnchor" id="H2324956"><span class="h3">Second-line interventions</span><span class="headingEndMark"> — </span>Patients who fail to improve adequately with behavioral interventions and who desire additional treatment may benefit from medical intervention. Options include light-based modalities and pharmacologic agents.</p><p class="headingAnchor" id="H3938375797"><span class="h4">Laser and intense pulsed light</span><span class="headingEndMark"> — </span>Laser and light-based therapies, which have been used extensively for the treatment of a variety of vascular lesions, have also been used for the vascular features of rosacea, especially telangiectasias. During treatment, light energy is absorbed by hemoglobin in cutaneous vessels, leading to vessel heating and coagulation. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Principles of laser therapy'</a>.)</p><p>Vascular lesions are commonly treated with lasers that emit green or yellow light (eg, pulsed dye or potassium titanyl phosphate [KTP] lasers) due to the relatively high absorption of light in these ranges by hemoglobin  (<a class="graphic graphic_figure graphicRef74419" href="/z/d/graphic/74419.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef72989" href="/z/d/graphic/72989.html" rel="external">table 1</a>). Intense pulsed light devices, which are also frequently used for this indication, are lower energy light sources that emit noncoherent light in a broad range of wavelengths. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Types of vascular lasers'</a>.)</p><p>Improvement in both facial erythema and telangiectasias can occur after treatment with pulsed dye lasers, KTP lasers, or intense pulsed light [<a href="#rid17">17,30-43</a>]. Most data on the efficacy of these modalities are derived from small, randomized controlled trials and uncontrolled studies. One split-face, randomized trial compared treatment with a pulsed dye laser with nonpurpuragenic settings to intense pulsed light and no treatment in 29 patients with rosacea. The two therapies were similarly beneficial for facial erythema and telangiectasias [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Telangiectasias and the red face'</a>.)</p><p>Near infrared lasers can be used to treat large, deep telangiectasias but are associated with increased risk for adverse effects  (<a class="graphic graphic_table graphicRef72989" href="/z/d/graphic/72989.html" rel="external">table 1</a>). Improvement in other clinical features, such as flushing, skin sensitivity, and skin texture, have also been reported in patients treated with laser or intense pulsed light therapy [<a href="#rid17">17,19,44</a>].</p><p>Light-based modalities do not cure rosacea, and periodic treatments to maintain improvement are often required. Potential adverse effects of laser and intense pulsed light therapy include skin dyspigmentation, blistering, ulceration, and scarring.</p><p class="headingAnchor" id="H501291"><span class="h4">Pharmacologic therapy</span><span class="headingEndMark"> — </span>The pharmacologic agent with the strongest evidence for efficacy for persistent facial erythema in rosacea is topical <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> [<a href="#rid45">45</a>]. Data from studies in patients with papulopustular rosacea suggest that medications primarily used for papulopustular disease (eg, topical antimicrobials, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, and oral antibiotics) may also have benefit for the reduction of rosacea-associated facial erythema [<a href="#rid46">46-54</a>]. However, no high-quality randomized trials have evaluated the efficacy of these therapies in patients without papules and pustules. In our experience, satisfactory improvement in persistent facial erythema with medications used for papulopustular disease is uncommon. Telangiectasias are particularly unlikely to improve with medications and are best managed with light-based treatments. (See <a class="local">'Laser and intense pulsed light'</a> above.) </p><p class="headingAnchor" id="H86757015"><span class="h5">Topical brimonidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">Brimonidine</a> tartrate, a vasoconstrictive alpha-2 adrenergic receptor agonist used in the treatment of open angle glaucoma, has emerged as a treatment for rosacea-associated facial erythema [<a href="#rid45">45</a>]. The efficacy of this agent when applied topically is supported by the results of phase II and phase III randomized trials [<a href="#rid55">55,56</a>]. In 2013, the US Food and Drug Administration (FDA) approved brimonidine 0.33% gel for the treatment of persistent (nontransient) facial erythema of rosacea based upon the findings of two 29-day placebo-controlled randomized trials conducted in a total of 553 adults with moderate to severe persistent facial erythema of rosacea [<a href="#rid57">57</a>]. At the end of the study, at least two-grade reductions in both clinician and patient assessment scales were achieved three hours after application by 31 and 25 percent of patients treated with brimonidine 0.33% gel versus only 11 and 9 percent of patients treated with vehicle. The efficacy of topical brimonidine has not been directly compared with laser or intense pulsed light therapy. </p><p>Topical <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> 0.33% gel appears to be well tolerated [<a href="#rid57">57,58</a>]. An open-label study in which women applied a 0.5% formulation of brimonidine tartrate gel supports the potential for continued safety and efficacy of topical brimonidine over one year of treatment [<a href="#rid59">59</a>]. The most common adverse effects are erythema, flushing, skin burning sensation, and contact dermatitis. The occurrence of severe, transient rebound erythema several hours after application has been reported [<a href="#rid60">60,61</a>]. An occurrence of persistent erythema in skin adjacent to the site of long-term brimonidine application also has been reported [<a href="#rid62">62</a>]. The true incidence of worsening erythema is not known but has been estimated to be up to 20 percent [<a href="#rid63">63</a>]. Patients should be counseled about these side effects prior to therapy.</p><p>The effect of <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> on papulopustular lesions of rosacea has not been specifically studied. Topical brimonidine has not appeared to aggravate papulopustular lesions of rosacea in randomized trials evaluating its efficacy for facial erythema [<a href="#rid55">55,56</a>]. Our experience suggests that brimonidine is not effective for the treatment of papulopustular lesions. Use in conjunction with other therapies may be beneficial for patients with both erythema and papulopustular lesions [<a href="#rid64">64</a>]. (See <a class="local">'Papules and pustules'</a> below.)</p><p class="headingAnchor" id="H1324472351"><span class="h5">Topical oxymetazoline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">Oxymetazoline</a>, an alpha-adrenergic receptor agonist used for the treatment of nasal congestion, may have modest efficacy for facial erythema in rosacea [<a href="#rid45">45</a>].</p><p>The 2017 FDA approval of <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">oxymetazoline</a> 1% cream for reducing persistent facial erythema associated with rosacea in adults was based upon two randomized trials in which a total of 885 adults with rosacea applied either oxymetazoline or vehicle once daily for 29 days [<a href="#rid65">65,66</a>]. More patients in the oxymetazoline groups achieved the primary efficacy endpoint (at least a two-grade reduction in erythema from baseline on both a five-point clinician erythema assessment scale and a five-point patient self-assessment scale at 3, 6, 9, and 12 hours after application) than in the vehicle groups. On day 29 in the first trial, 12 and 6 percent of patients receiving oxymetazoline and vehicle, respectively, achieved this endpoint three hours after application. In the second trial, this was achieved at the same time point by 14 and 7 percent of patients in the oxymetazoline and vehicle groups, respectively. Potential side effects of oxymetazoline include application site dermatitis, worsening of inflammatory rosacea lesions, pain, pruritus, and erythema.</p><p>A 52-week, open-label study (REVEAL study) of 440 patients treated with <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">oxymetazoline</a> for moderate to severe facial erythema of rosacea supports long-term efficacy and tolerability [<a href="#rid67">67</a>]. In this study, less than 1 percent of patients experienced post-treatment rebound erythema; however, data from postmarketing surveillance is pending. The REVEAL study also demonstrated increased chance of meaningful treatment response with prolonged use, thus suggesting that best clinical results may come from daily, long-term, continued use of oxymetazoline [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H4133185593"><span class="h5">Additional safety considerations</span><span class="headingEndMark"> — </span>Because of concern for risk for potentiation of vascular insufficiency and hypotension during treatment with alpha-2 adrenergic agonists, cautious use is recommended in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, Sjögren's disease, and severe cardiovascular disease. Caution is also recommended for patients who are receiving treatment with antihypertensives, cardiac glycosides, central nervous system depressants, and monoamine oxidase inhibitors. Ingestion of <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> may result in serious adverse effects and should be avoided.</p><p class="headingAnchor" id="H3386960909"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Additional studies are required to determine the value of topical retinoids [<a href="#rid69">69,70</a>], licochalcone A (an ingredient derived from the licorice plant) [<a href="#rid71">71</a>], oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid27">27</a>], oral <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> [<a href="#rid72">72</a>], topical <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> [<a href="#rid73">73</a>], dual-frequency ultrasound [<a href="#rid74">74</a>], microfocused ultrasound [<a href="#rid75">75</a>], and botulinum toxin injections in the treatment of facial redness and skin sensitivity in rosacea. The role of topical calcineurin inhibitors (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>) in this presentation of rosacea is uncertain. Improvement with topical tacrolimus has been reported in small numbers of patients [<a href="#rid76">76,77</a>].</p><p class="headingAnchor" id="H2325345"><span class="h1">PAPULES AND PUSTULES</span><span class="headingEndMark"> — </span>Rosacea can present with inflammatory papules and/or pustules primarily distributed on the central face. Patients often also exhibit persistent facial erythema, frequent flushing, and telangiectasias. </p><p class="headingAnchor" id="H2325353"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>Most patients with mild to moderate disease  (<a class="graphic graphic_picture graphicRef67890 graphicRef53889" href="/z/d/graphic/67890.html" rel="external">picture 1C, 1F</a>) can be managed with topical therapies such as <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, or <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a>. Systemic agents are typically used in patients who fail to respond satisfactorily to topical agents or who present with numerous inflammatory lesions  (<a class="graphic graphic_picture graphicRef78747" href="/z/d/graphic/78747.html" rel="external">picture 1D</a>). Tetracycline-class antibiotics are first-line systemic agents for papules and pustules of rosacea; for patients who fail to respond to tetracyclines or who cannot tolerate these drugs, treatment with other oral antibiotics is an option. Laser therapy, intense pulsed light, and photodynamic therapy have also been used, but the efficacy of these therapies remains uncertain.</p><p class="headingAnchor" id="H2325879"><span class="h3">Mild to moderate disease</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, and topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> are considered first-line therapies in mild to moderate disease  (<a class="graphic graphic_picture graphicRef59815 graphicRef53889" href="/z/d/graphic/59815.html" rel="external">picture 1F-G</a>) due to evidence from randomized trials in support of their efficacy and the relative safety of these medications. A systematic review found high-quality evidence to support the efficacy of these drugs [<a href="#rid78">78</a>]. Other agents, such as <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a>, also may be beneficial.</p><p class="headingAnchor" id="H2325366"><span class="h4">Topical metronidazole</span><span class="headingEndMark"> — </span>The mechanism through which <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> improves rosacea is unknown, but may involve antimicrobial, anti-inflammatory, or antioxidant properties [<a href="#rid79">79</a>]. Topical metronidazole is most effective for the treatment of inflammatory papules and pustules, but may also contribute to improvement in facial erythema. </p><p>A systematic review of randomized trials performed primarily in patients with papulopustular features of rosacea found moderate certainty evidence in support of the use of topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid45">45</a>]. Metronidazole was superior to placebo (relative risk [RR] 1.98; 95% CI 1.29-3.02). </p><p>Topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is available as a 0.75% cream or gel, a 1% cream or gel, and a 0.75% lotion. Unlike 1% formulations, which are labeled for once-daily application, drug labels for 0.75% formulations recommend twice daily use. However, the product concentration, frequency of application, and vehicle (cream, gel, or lotion) may not significantly affect treatment efficacy:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 12-week single-blind randomized trial that compared once-daily application of 0.75% cream with once-daily application of 1% cream in 72 patients with papulopustular presentations, no significant difference in the percent reduction in median inflammatory lesion counts (62 versus 60 percent) or erythema scores (26 versus 30 percent) was detected [<a href="#rid80">80</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from a meta-analysis of randomized placebo-controlled trials were insufficient to draw definitive conclusions on the relative efficacy of once versus twice daily dosing [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials comparing <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% cream versus 0.75% gel and 0.75% gel versus 0.75% lotion have found similar treatment efficacy [<a href="#rid78">78,81</a>].</p><p></p><p>The data above suggest that once daily application of 0.75% <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> may be sufficient, but additional studies are necessary. The drug vehicle should be selected based upon patient preference and tolerability.</p><p>Improvement in inflammatory lesions may occur after as few as two to four weeks of therapy, but full results are typically observed after eight to nine weeks of treatment [<a href="#rid82">82-85</a>]. Relapses often occur when <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is discontinued; thus, long-term therapy is usually needed [<a href="#rid86">86</a>]. </p><p>Topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is generally well tolerated; the most common adverse effects are local irritation, dryness, and stinging sensations [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H2325386"><span class="h4">Topical azelaic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">Azelaic acid</a> is a naturally occurring dicarboxylic acid with anti-inflammatory and antioxidative properties. Similar to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, azelaic acid improves papular and pustular lesions, and may also reduce erythema. The mechanism of action for azelaic acid in rosacea is not well understood. Reductions in messenger RNA for cathelicidin and kallikrein 5, potential contributors to the development of rosacea, have been detected following treatment with topical azelaic acid in patients with rosacea [<a href="#rid87">87</a>]. Azelaic acid-induced modulation of the inflammatory response via activation of peroxisome proliferator-activated receptor-gamma is an additional potential mechanism of action [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Immune dysfunction'</a>.)</p><p><a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">Azelaic acid</a> is available as a 20% cream or lotion, or as a 15% foam or gel [<a href="#rid89">89</a>]. The cream, foam and gel formulations are available in the United States. </p><p>The utility of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> for rosacea is supported by a systematic review of randomized trials performed primarily in patients with papulopustular rosacea that found high certainty evidence to support this therapy. Azelaic acid was a more effective treatment than placebo (RR 1.40, 95% CI 1.28-1.53) [<a href="#rid45">45</a>]. Examples of trials demonstrating efficacy of this agent include:</p><p class="bulletIndent1"><span class="glyph">●</span>Two 12-week vehicle-controlled randomized trials with a total of 664 patients with papules, pustules, persistent erythema, and telangiectasia found significantly greater mean reductions in inflammatory lesions in patients treated with twice-daily applications of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> 15% gel than in the vehicle group (58 versus 40 percent and 51 versus 39 percent, respectively) [<a href="#rid47">47</a>]. Patients in the active treatment group were also more likely to exhibit improvement in erythema (44 versus 29 percent and 46 versus 28 percent, respectively). Facial telangiectasias did not respond to therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A three-month vehicle-controlled randomized trial in 116 patients with papules, pustules, persistent erythema, and telangiectasia found that twice-daily application of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> 20% cream led to superior mean percent reductions in inflammatory lesion counts (73 versus 50 percent) and erythema severity scores (48 versus 38 percent) [<a href="#rid90">90</a>].</p><p></p><p>Initial improvement from <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> may be noted within the first few weeks of use. Better results are typically observed after 12 to 15 weeks of therapy [<a href="#rid85">85</a>].</p><p>Although package inserts for <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> recommend twice daily application, a randomized trial in 72 patients treated with the 15% gel failed to identify a difference in efficacy between once daily and twice daily dosing, suggesting that once daily application may be sufficient for improvement [<a href="#rid91">91</a>]. Rates of adverse effects and treatment tolerability were similar in the two groups. </p><p>The most frequent side effect of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> is skin discomfort after application [<a href="#rid90">90,92,93</a>]. In two randomized trials in which a total of 333 patients were treated with azelaic acid 15% gel, 38 percent of patients reported burning, itching, or stinging sensations [<a href="#rid47">47</a>]. Symptoms were transient and mild to moderate in the majority of patients, and less than 1 percent of all patients had severe, persistent sensory symptoms.</p><p class="headingAnchor" id="H16743134"><span class="h5">Azelaic acid versus metronidazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">Azelaic acid</a> appears to be at least equally as effective as <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for the treatment of papules and pustules in rosacea, and some trials have demonstrated superior efficacy [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest randomized trial (n = 251) comparing <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> in patients with papules, pustules, persistent erythema, and telangiectasia found that twice-daily application of azelaic acid 15% gel for up to 15 weeks was superior to twice-daily application metronidazole 0.75% gel [<a href="#rid85">85</a>]. Azelaic acid was associated with significantly greater mean reductions in inflammatory lesion counts (73 versus 56 percent with metronidazole) and a higher rate of improvement in erythema (56 versus 42 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 15-week investigator-blinded randomized trial in 160 patients that compared twice-daily applications of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> 15% gel with once-daily applications of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 1% gel found similar improvements in inflammatory lesion counts and erythema [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 15-week split-face randomized trial (n = 40) in which twice daily application of <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> 20% cream was compared with twice daily application of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% cream found similar improvements with the two preparations in inflammatory lesions, erythema, and skin dryness, and no difference in burning sensations related to rosacea [<a href="#rid48">48</a>]. Stinging sensations associated with drug application were more frequent in patients treated with azelaic acid. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial (n = 24) comparing <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> 20% cream, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% cream, and <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a> 5% cream found that azelaic acid was superior to the other therapies for the treatment of inflammatory lesions [<a href="#rid95">95</a>]. The three agents had similar benefit for erythema. </p><p></p><p class="headingAnchor" id="H644355660"><span class="h4">Topical ivermectin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">Ivermectin</a> is an agent with both anti-inflammatory and antiparasitic properties. The drug is commercially available for the treatment of inflammatory lesions of rosacea as a 1% cream. Ivermectin 1% cream is applied once daily. A pea-sized amount is applied to each affected area of the face (eg, forehead, chin, nose, each cheek) and spread into a thin layer [<a href="#rid96">96</a>]. </p><p>Use of topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 1% cream for papular and pustular lesions of rosacea is supported by two high-quality, vehicle-controlled, randomized trials that demonstrated efficacy in adults with moderate to severe rosacea (defined in the study as 15 to 70 inflammatory papules or pustules) [<a href="#rid45">45,97</a>]. In the first trial, 173 of 451 patients (38 percent) treated with ivermectin were clear or almost clear of inflammatory lesions after 12 weeks. In contrast, this endpoint was achieved by only 27 of 232 patients (12 percent) in the vehicle group. The results of the second trial were similar; after 12 weeks, 184 of 459 patients (40 percent) treated with ivermectin versus 43 of 229 patients (19 percent) given vehicle were clear or almost clear of inflammatory lesions. </p><p>Treatment with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> cream is well tolerated. A long-term safety study found use of topical ivermectin 1% cream safe and effective for up to 52 weeks [<a href="#rid98">98</a>].</p><p>The efficacy of topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> may be related to anti-<em>Demodex</em> and anti-inflammatory activity. Of note, patients in the randomized trials were not evaluated for <em>Demodex</em> infestation prior to therapy. A retrospective study of 50 patients with rosacea papules and pustules treated with topical ivermectin once daily found both a reduction in <em>Demodex</em> mites and clinical improvement after 16 weeks of treatment [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H739918776"><span class="h5">Ivermectin versus metronidazole</span><span class="headingEndMark"> — </span>A 16-week randomized trial that compared once-daily use of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 1% cream with twice-daily use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% cream in 962 adults with moderate to severe rosacea presenting with papules, pustules, and erythema found that topical ivermectin was more effective for reducing inflammatory lesions [<a href="#rid100">100</a>]. Moreover, a 36-week extension phase of this study revealed longer remissions after treatment with topical ivermectin than after treatment with topical metronidazole (115 versus 85 days) [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H1795482549"><span class="h4">Choice of treatment</span><span class="headingEndMark"> — </span>Based upon these observations, topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, and <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> are reasonable choices for first-line topical therapy for papules and pustules in rosacea. The lower cost of metronidazole 0.75% gel (the least expensive formulation of metronidazole) compared with azelaic acid and ivermectin favors the initial use of metronidazole. We also favor metronidazole or ivermectin in patients who present with significant facial sensitivity, due to the fairly frequent occurrence of irritation early in the course of therapy with azelaic acid [<a href="#rid90">90,92,93,98</a>]. (See <a class="local">'Topical azelaic acid'</a> above.)</p><p class="headingAnchor" id="H692959325"><span class="h4">Alternative topical agents</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> has emerged as an additional treatment option for papulopustular manifestations of rosacea based upon data from randomized trials. Less well-studied topical agents used for the management of rosacea include topical <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a>, <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, topical retinoids, and <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a>. We generally utilize these agents in patients who cannot tolerate or obtain <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, or <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> or who fail to respond to those therapies but prefer to avoid oral agents.</p><p class="headingAnchor" id="H1180398586"><span class="h5">Topical minocycline</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> 1.5% foam is applied once daily to affected areas.</p><p>Two identical, 12-week, phase 3, randomized trials (n = 751 and n = 771) support the efficacy of topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> for papulopustular manifestations of rosacea [<a href="#rid102">102</a>]. In the trials, adults with moderate to severe papulopustular rosacea were randomly assigned in a 2:1 ratio to once-daily application of either minocycline 1.5% foam or vehicle foam to the entire face. Greater reductions in inflammatory lesion counts at week 12 occurred in the minocycline groups in both trials. Similarly, more patients in the minocycline groups achieved treatment success (defined as at least a two-grade improvement on the five-point Investigator's Global Assessment scale).</p><p>Treatment with topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> was generally well tolerated. No serious adverse events occurred. Minocycline-induced skin dyspigmentation, a potential adverse effect of oral minocycline, was not reported. An open-label, extension study of the aforementioned trials of minocycline foam did not demonstrate any dyspigmentation in subjects using minocycline foam up to 52 weeks [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H2325624"><span class="h5">Sulfacetamide-sulfur</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">Sulfacetamide-sulfur</a> is available in a variety of formulations, including topical suspensions, lotions, cleansers, creams, foams, and cleansing pads. The most common concentration is <a class="drug drug_general" data-topicid="9958" href="/z/d/drug information/9958.html" rel="external">sulfacetamide</a> 10% with sulfur 5%. Other drug concentrations and formulations with added sunscreen or cosmetically-beneficial green coloring are also available (see <a class="local">'Cosmetic camouflage'</a> above). The mechanism of action of sulfacetamide-sulfur in rosacea is unknown.</p><p>In comparison to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, data on the efficacy of <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a> are limited. A vehicle-controlled randomized trial in 103 patients and an open-label study in 59 patients reported benefit of this agent for inflammatory lesions and erythema [<a href="#rid104">104,105</a>]. Additional studies are necessary to confirm the results of a 12-week randomized trial of 152 patients that found that a <a class="drug drug_general" data-topicid="9958" href="/z/d/drug information/9958.html" rel="external">sulfacetamide</a> 10%-sulfur 5% cream containing sunscreen was superior to metronidazole 0.75% cream for the reduction of pustular, but not papular, lesions [<a href="#rid106">106</a>].</p><p>Side effects of <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a> include local irritation and allergic reactions [<a href="#rid27">27,104</a>]. Use of sulfacetamide-sulfur should be avoided in patients with sulfonamide ("sulfa") allergies [<a href="#rid27">27</a>]. Of note, some patients find the odor of sulfacetamide-sulfur agents unfavorable.</p><p class="headingAnchor" id="H25403012"><span class="h5">Other therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other topical antimicrobials </strong>–<strong> </strong>In a 12-week randomized trial of 53 patients with rosacea with persistent erythema, telangiectases, papules, and pustules, a gel containing a combination of <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> 5% and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 1% was superior to vehicle for the reduction of papulopustules (mean percent reduction 71 versus 19 percent), erythema, and flushing/blushing [<a href="#rid50">50</a>]. Monotherapy with clindamycin or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> may also be beneficial; clindamycin lotion was as effective as <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> in one randomized trial of 43 patients in whom papules and pustules were a major manifestation of their disease [<a href="#rid49">49</a>], and erythromycin solution was associated with improvement in papulopustules and erythema in an open-label study of 15 patients [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical retinoids </strong>– Topical retinoids, which are known to have anti-inflammatory and extracellular matrix repair properties, have been studied for the treatment of papules and pustules in rosacea with variable results. In a 12-week randomized trial that compared <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">adapalene</a> 0.1% gel with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel in 55 patients with papulopustular rosacea, adapalene was associated with significantly greater reductions in inflammatory lesions [<a href="#rid108">108</a>]. Unlike metronidazole, adapalene did not induce significant improvement in erythema. Although improvement in papulopustular lesions was observed after <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">topical tretinoin</a> therapy in a small randomized trial (n = 22) that compared treatment with tretinoin 0.025% cream to oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid69">69</a>], a subsequent randomized trial (n = 79) that compared once-daily application of a gel containing tretinoin 0.025% and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 1.2% to placebo failed to find a statistically significant difference in effect on papulopustular lesions between the two groups [<a href="#rid109">109</a>]. Additional studies are necessary to confirm the effects of topical retinoids on papulopustular lesions of rosacea. Skin irritation is a potential adverse effect of topical retinoids. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Permethrin</strong><strong> </strong>– Although a causal relationship between <em>Demodex</em> mites and rosacea is uncertain, topical <a class="drug drug_general" data-topicid="9759" href="/z/d/drug information/9759.html" rel="external">permethrin</a>, an antiparasitic agent, may have benefit for the treatment of rosacea. In a randomized trial of 63 patients with papulopustular rosacea that compared treatment with permethrin 5% cream, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel, and placebo, improvement with permethrin was equivalent to metronidazole and superior to placebo [<a href="#rid110">110</a>]. The validity of these results may be questionable due to the close clinical resemblance of <em>Demodex</em> folliculitis to rosacea. The safety of long-term permethrin use also is unknown. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Microorganisms'</a>.)</p><p></p><p>Topical calcineurin inhibitors do not appear to be beneficial for papulopustular rosacea. Small placebo controlled randomized trials failed to find statistically superior efficacy for <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream [<a href="#rid111">111,112</a>], and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment was not effective for papulopustular lesions in a small uncontrolled study [<a href="#rid77">77</a>]. In addition, the development of rosacea-like cutaneous eruptions has been reported in patients treated with topical tacrolimus for other indications [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H2325908"><span class="h3">Moderate to severe disease</span><span class="headingEndMark"> — </span>Patients who present with numerous inflammatory papules or pustules  (<a class="graphic graphic_picture graphicRef78747" href="/z/d/graphic/78747.html" rel="external">picture 1D</a>), or those with milder disease that fails to respond to one or more topical therapies may benefit from oral antibiotic therapy. Of the oral antibiotics, tetracyclines are the best-studied agents.</p><p class="headingAnchor" id="H2325871"><span class="h4">Oral tetracyclines</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> have been used for many years for the management of rosacea. These agents are most useful for improving inflammatory papules and pustules, and may also reduce erythema [<a href="#rid51">51,53</a>].</p><p>Since no definitive microbial cause of rosacea has been identified, the efficacy of oral antibiotics in rosacea is often attributed to their anti-inflammatory properties [<a href="#rid114">114</a>]. Tetracyclines may decrease levels of proinflammatory cathelicidins (components of the innate immune system) through inhibition of serine proteases, may reduce levels of proinflammatory cytokines, and may have matrix-protecting capabilities [<a href="#rid114">114,115</a>]. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Immune dysfunction'</a>.)</p><p class="headingAnchor" id="H264219"><span class="h5">Efficacy and administration</span><span class="headingEndMark"> — </span>Traditional, antimicrobial doses for <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> are 250 to 1000 mg per day and 100 to 200 mg per day for <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid116">116,117</a>]. Few placebo-controlled randomized trials have evaluated the efficacy of these doses in rosacea. In two early, small trials, tetracycline (250 mg twice daily for four to eight weeks or 750 mg per day for one week followed by 250 mg to 500 mg per day for five weeks) was associated with improvement in inflammatory lesions [<a href="#rid51">51,118</a>]. In addition, randomized trials comparing doxycycline with other oral antibiotics found that a 100 mg per day dose of doxycycline effectively improves papulopustular rosacea [<a href="#rid54">54,119</a>]. (See <a class="local">'Alternative oral antibiotics'</a> below.)</p><p>Due to concern for the development of antibiotic resistance, interest has grown in the use of subantimicrobial doses of antibiotics, which retain anti-inflammatory properties but lack antibacterial effects. Support for the efficacy of subantimicrobial doses of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (20 mg taken twice daily or a combination pill containing 30 mg of immediate release doxycycline and 10 mg of delayed release doxycycline taken once daily) come from both randomized trials [<a href="#rid120">120,121</a>] and an open label study of almost 1200 patients [<a href="#rid53">53</a>]. In two 16-week placebo-controlled randomized trials performed in 537 patients with 10 to 40 inflammatory lesions, doxycycline was associated with significantly greater reductions in inflammatory lesion counts [<a href="#rid120">120</a>]. In addition, one of the two trials and the open-label study found improvement in erythema [<a href="#rid53">53</a>]. </p><p>Few randomized trials have compared subantimicrobial dose <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> with higher doses of oral tetracyclines. One randomized trial with 91 patients compared subantimicrobial dose doxycycline (40 mg once daily) with doxycycline 100 mg per day [<a href="#rid122">122</a>]. Both doses were similarly effective for the treatment of inflammatory lesions, but the lower dose was associated with a reduced rate of gastrointestinal side effects (5 versus 26 percent). In addition, a 16-week trial that compared doxycycline (40 mg once daily) with <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (100 mg once daily) found similar reductions in lesion counts in both groups [<a href="#rid123">123</a>].</p><p>We typically initiate treatment with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> 100 mg twice daily, or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> 500 mg twice daily and continue treatment for 4 to 12 weeks in an attempt to quickly decrease inflammation. Initiating treatment with subantimicrobial dose doxycycline is another reasonable option. We generally favor doxycycline over minocycline for initial treatment because of minocycline's broader side effect profile.</p><p>After satisfactory improvement is attained with the initial course of therapy, we transition patients to a topical agent, most often <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a> (see <a class="local">'Topical metronidazole'</a> above and <a class="local">'Topical azelaic acid'</a> above). Continuing oral therapy at the lowest effective dose is another option in patients who fail to maintain improvement or who are unable to tolerate topical therapy [<a href="#rid3">3</a>]. Subantimicrobial dose <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is our preferred choice for long-term oral therapy. </p><p>Patients who respond well to topical maintenance therapy may have occasional "break-through" flares of papulopustular lesions spaced by several months or more. For such patients, we have found the administration of an abbreviated course of an oral antibiotic (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily for 10 days) useful for quieting the acute flares, circumventing the need for long-term oral therapy. These patients are continued on topical maintenance therapy during and after oral treatment.</p><p>Adverse effects of oral tetracyclines include gastrointestinal distress and photosensitivity. <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> is the least photosensitizing of these agents, but it may cause vertigo, a lupus-like syndrome, and skin discoloration. Tetracyclines should <strong>not</strong> be given to children under the age of nine due to a risk for permanent tooth discoloration and reduced bone growth.</p><p class="headingAnchor" id="H689662"><span class="h5">Combined with topical agents</span><span class="headingEndMark"> — </span>Adding an oral antibiotic to topical therapy may improve treatment results. Two randomized trials that compared treatment with topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> alone to topical metronidazole plus subantimicrobial dose <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> found superior improvement in inflammatory lesions with combination therapy [<a href="#rid121">121,124</a>]. In an investigator-blinded, 12-week, randomized trial (n = 273), the combination of 40 mg per day of doxycycline and daily application of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 1% cream was associated with greater efficacy and faster improvement in papulopustular manifestations of severe rosacea compared with monotherapy with ivermectin 1% cream [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H2326144"><span class="h4">Alternative oral antibiotics</span><span class="headingEndMark"> — </span>Other oral antibiotics are less frequently used for the treatment of rosacea, but may also be effective. These include macrolides (<a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) and oral <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid27">27,52,54,119</a>]. </p><p>An eight-week randomized trial comparing <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> (250 mg twice daily for four weeks followed by 250 mg daily for four weeks) with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily for four weeks followed by 100 mg once daily for four weeks) found significantly greater improvement in objective measures of inflammatory lesions, erythema, and telangiectasias in patients treated with clarithromycin at early study time points, but differences among the two groups dissipated by week eight [<a href="#rid54">54</a>]. A separate 12-week trial that compared <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg three times per week followed by a taper) with doxycycline 100 mg daily found that the drugs were similarly effective [<a href="#rid119">119</a>]. </p><p>Oral <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is commonly used for the treatment of rosacea in Europe. In a randomized trial of 40 patients that compared treatment with metronidazole (200 mg twice daily) to oxytetracycline (250 mg twice daily), the agents appeared to be similarly effective [<a href="#rid126">126</a>]. Alcohol should be avoided during treatment with metronidazole due to the possibility of the induction of a disulfiram-like reaction.</p><p class="headingAnchor" id="H693879"><span class="h3">Refractory disease</span></p><p class="headingAnchor" id="H693795"><span class="h4">Oral isotretinoin</span><span class="headingEndMark"> — </span>Patients who fail to respond to topical therapies and oral antibiotics may improve with oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid69">69,127-129</a>]. Oral isotretinoin is not used as first-line therapy due to the drug's many adverse effects, including teratogenicity. In the United States, oral isotretinoin can only be prescribed through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F%23Main&amp;token=11npaxc5%2BtwYQNEbNxIvNQfcJaSKzBwVKphwr4ut8b7qoeyGYSAd9yUzO5kFibik&amp;TOPIC_ID=16632" target="_blank">iPLEDGE program</a>, an internet-based risk management program. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Teratogenicity'</a> and  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Adverse effects'</a>.)</p><p>Although improvement in inflammatory lesions and facial erythema has been reported in several randomized trials and observational studies [<a href="#rid69">69,127-129</a>], high-quality data on the efficacy of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for rosacea are scarce, and the ideal regimen for treatment has not been established. Doses of 0.5 to 1 mg/kg per day have been utilized in some patients, but lower doses may be effective and better-tolerated. </p><p>The authors of a 12-week dose-comparison randomized trial reported a 90 percent reduction of inflammatory lesions in patients treated with 0.3 mg/kg per day [<a href="#rid129">129</a>]. Additionally, compared with patients who were treated with 0.5 mg/kg/day, these patients had a lower incidence of drug-related facial dermatitis. </p><p>In another randomized trial, 156 patients with papulopustular rosacea that had failed to respond to three or more previous treatments were treated with low-dose <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (0.25 mg/kg) or placebo daily for four months [<a href="#rid130">130</a>]. The primary endpoint was a reduction in the lesion number of at least 90 percent. At the end of the study, more patients in the isotretinoin group than those in the placebo group reached the primary endpoint (57 versus 10 percent, absolute difference 47 percent, 95% CI 34 to 60 percent; number needed to treat 2). Adverse effects, including cheilitis, dry skin, and abdominal pain, were more common in the isotretinoin group than in the placebo group (69 versus 44 percent). Patients were followed for 4 months after isotretinoin completion. Rosacea relapsed in 53 percent of patients who responded to isotretinoin after a median time of 15 weeks.</p><p>We typically treat patients with around 0.2 mg/kg per day (usually a total of 10 to 20 mg per day) until the inflammatory component is consistently well controlled for one to two months. In our experience, this usually occurs after five to six months of therapy.</p><p>The longevity of treatment effect varies; in a series of 20 patients with severe rosacea treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> doses of 0.5 to 1 mg/kg per day for three to six months, remissions lasting at least one year were reported in 17 patients [<a href="#rid131">131</a>]. Of note, five out of six patients initially treated with 1 mg/kg per day required dose reductions due to adverse effects. The remission period may be shorter in patients treated with low-doses [<a href="#rid130">130</a>].</p><p>After completion of a successful course of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, we routinely initiate maintenance therapy with topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, or other standard therapies for pustular rosacea in an attempt to increase the likelihood of sustained remission. However, the efficacy of this approach has not been studied.</p><p class="headingAnchor" id="H25403507"><span class="h3">Laser and intense pulsed light</span><span class="headingEndMark"> — </span>Treatment with light-based therapies has yielded variable results in patients with papules and pustules. Although the results of two uncontrolled studies utilizing intense pulsed light or pulsed dye laser suggest that some improvement in inflammatory papules is possible [<a href="#rid132">132,133</a>], other studies have found conflicting results [<a href="#rid35">35,134,135</a>], and there is insufficient evidence to conclude that improvement is long-lasting. </p><p>Photodynamic therapy, which involves the application of a photosensitizing agent (<a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">aminolevulinic acid</a> or methyl aminolevulinic acid) to skin and exposure of the treatment site to a light source, has also yielded mixed results. Improvement in inflammatory lesions lasting three months or longer was reported in a small retrospective study and two out of four patients in a case series [<a href="#rid136">136,137</a>]; however, in another case series, disease severity returned to baseline in three out of four patients within 12 weeks after treatment [<a href="#rid134">134</a>].</p><p class="headingAnchor" id="H689748"><span class="h2">Maintenance therapy</span><span class="headingEndMark"> — </span>Because rosacea is a chronic disorder and treatments are not curative, continued therapy is typically necessary to maintain treatment response. Most commonly, long-term topical therapy is administered. Subantimicrobial doses of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> are also an option. (See <a class="local">'Oral tetracyclines'</a> above.)</p><p class="headingAnchor" id="H695717"><span class="h1">OCULAR MANIFESTATIONS</span><span class="headingEndMark"> — </span>Ocular involvement may occur in the presence or absence of cutaneous manifestations. Examples of features of ocular rosacea include foreign body sensations, blepharitis, lid margin telangiectasia, tear abnormalities, meibomian gland inflammation, frequent chalazion, conjunctivitis, and rarely, corneal ulcers and vascularization [<a href="#rid138">138</a>]. Patients who present with signs or symptoms of ocular involvement should be referred to an ophthalmologist for further evaluation. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p>Lid scrubs and warm compresses may help improve meibomian gland function [<a href="#rid139">139</a>], and topical antibiotics such as topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> may quell mild lid inflammation [<a href="#rid138">138,140,141</a>]. For those with moderate to severe ocular rosacea, short courses of oral tetracycline-class antibiotics, macrolide antibiotics, or metronidazole are often needed [<a href="#rid140">140,142,143</a>]. Topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may also minimize inflammation [<a href="#rid144">144</a>].</p><p class="headingAnchor" id="H694796"><span class="h1">PHYMATOUS SKIN CHANGES</span><span class="headingEndMark"> — </span>Tissue hypertrophy, dilated follicles, and irregular nodular overgrowths are characteristic features of the phymatous skin changes of rosacea. These changes most commonly affect the nose (rhinophyma), but may also affect other areas such as the chin, cheeks, and ears  (<a class="graphic graphic_picture graphicRef61822" href="/z/d/graphic/61822.html" rel="external">picture 1E</a>) [<a href="#rid7">7,145</a>]. Features of other subtypes of rosacea may also be present. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H694836"><span class="h2">Early disease</span><span class="headingEndMark"> — </span>The best approach to the treatment of early phymatous skin changes is unknown. Improvements in phymatous changes have been reported in patients treated with 0.3 to 1 mg/kg per day of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> administered for periods of 12 to 28 weeks [<a href="#rid129">129,146</a>]. The duration of benefit is uncertain.</p><p class="headingAnchor" id="H694922"><span class="h2">Advanced disease</span><span class="headingEndMark"> — </span>Laser ablation and surgical techniques can be used to debulk and recontour tissue distorted by phymatous changes. Ablative carbon dioxide lasers [<a href="#rid147">147</a>] and infrared diode lasers [<a href="#rid148">148,149</a>] have been used for this purpose. Surgical debulking can be performed through dermabrasion, scalpel excision, electrosurgery, or cryosurgery [<a href="#rid150">150,151</a>].</p><p>The potential side effects of laser and surgical interventions include hypopigmentation, scarring, and pain. The risk for pigmentary changes rises with increasing skin pigmentation.</p><p class="headingAnchor" id="H695009"><span class="h1">SPECIAL CASES</span></p><p class="headingAnchor" id="H695168"><span class="h2">Granulomatous rosacea</span><span class="headingEndMark"> — </span>Granulomatous rosacea may be a variant of rosacea. It presents with uniform red-brown or yellow-brown papules on the face. Other manifestations of rosacea may or may not be present [<a href="#rid152">152-154</a>]. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Granulomatous rosacea'</a>.)</p><p>Efficacy data on treatment for granulomatous rosacea are limited to case reports. Treatments are similar to those used for papulopustular rosacea. However, lesions may be slower to respond or less-likely to respond to therapy [<a href="#rid155">155,156</a>], and oral antibiotic therapy is often required [<a href="#rid156">156,157</a>]. Successful treatment with oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, topical <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>, and intense pulsed light has also been documented [<a href="#rid158">158-162</a>].</p><p class="headingAnchor" id="H695001"><span class="h2">Pediatric rosacea</span><span class="headingEndMark"> — </span>Infrequently, rosacea develops in children. All features, except for phymatous changes, may occur. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Epidemiology'</a>.) </p><p>As with adults, nonpharmacologic measures aimed at reducing symptoms are recommended. Mild to moderate papulopustular disease is usually managed with topical agents, such as <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, <a class="drug drug_general" data-topicid="10289" href="/z/d/drug information/10289.html" rel="external">sulfacetamide-sulfur</a>, and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> (see <a class="local">'Mild to moderate disease'</a> above). Oral antibiotics may be necessary for patients with more severe papulopustular eruptions. Because tetracyclines are contraindicated in children under the age of nine, oral erythromycin (30 to 50 mg/kg/day), <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> may be substituted as a first-line oral agent [<a href="#rid155">155,163</a>]. Oral metronidazole (20 to 30 mg/kg per day) has also been used in the treatment of children [<a href="#rid164">164</a>]. As in adults, after oral antibiotics produce a remission, treatment with a topical agent may be used to maintain clearance.</p><p>Ocular manifestations of rosacea are managed similarly as in adults, with the exclusion of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> antibiotic therapy in children under the age of nine. Systemic antibiotics may be required for several months to achieve complete remission [<a href="#rid165">165</a>]. Granulomatous rosacea in the pediatric population may respond to topical or oral antibiotics [<a href="#rid155">155,164</a>]. Several months of treatment may be required for improvement. </p><p class="headingAnchor" id="H695032"><span class="h2">Pyoderma faciale</span><span class="headingEndMark"> — </span>Pyoderma faciale (also known as rosacea fulminans) is an unusual eruption that is not officially recognized as a rosacea variant. The disorder is characterized by an abrupt onset of papules and suppurative nodules on the face [<a href="#rid166">166</a>]. Young women are most commonly affected [<a href="#rid167">167</a>]. (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Pyoderma faciale (rosacea fulminans)'</a>.)</p><p>Data on the treatment of pyoderma faciale are limited to reports of clinical experience. Patients can be managed with a combination of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. Prednisone is often started at 0.5 to 1 mg/kg per day and tapered over a period of weeks, and isotretinoin is initiated around two weeks after the start of prednisone therapy with low doses of 0.2 to 0.5 mg/kg per day [<a href="#rid163">163,167,168</a>]. During the steroid taper, the isotretinoin dose is slowly increased to 0.5 to 1 mg/kg per day as tolerated. Some authors advocate treating until a cumulative dose of 150 mg/kg has been attained [<a href="#rid168">168</a>]; others believe that isotretinoin can be discontinued once inflammatory lesions have resolved [<a href="#rid167">167</a>]. We typically treat until a cumulative dose of 120 to 150 mg/kg has been attained, provided treatment is tolerated.</p><p>Alternatives to the above regimen include initiation of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> along with a <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper as above [<a href="#rid167">167,169</a>]. Successful treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> has also been reported [<a href="#rid170">170</a>].</p><p class="headingAnchor" id="H3947941241"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117556.html" rel="external">"Society guideline links: Rosacea"</a>.)</p><p class="headingAnchor" id="H26656310"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Rosacea is a common disorder that presents with a variety of clinical findings. The phenotype of rosacea determines the approach to treatment. (See <a class="local">'Patient assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures </strong>– General measures to improve symptoms of flushing, erythema, and skin irritation can be beneficial for patients with rosacea. Patients should be educated on the avoidance of triggers of flushing, gentle skin care, and sun protection. Cosmetic camouflage is a useful adjunct for some patients. (See <a class="local">'Facial redness, flushing, skin sensitivity, and skin dryness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent facial erythema and telangiectasias </strong>– Behavioral modifications may improve persistent facial erythema, telangiectasias, flushing, and sensitive skin. If persistent facial erythema does not improve sufficiently with behavioral changes, therapeutic interventions can be useful. For patients who desire a topical therapy for facial erythema that can be self-administered, we suggest treatment with topical <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). Laser or intense pulsed light are additional effective treatment options for facial erythema. Periodic retreatment with laser or intense pulsed light is often necessary to maintain improvement. Facial telangiectasias are best managed with laser or intense pulsed light therapy. (See <a class="local">'Facial redness, flushing, skin sensitivity, and skin dryness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Papules and pustules </strong>– There are few data to support benefit of treatments effective for papules and pustules of rosacea (eg, topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, topical <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, or subantimicrobial <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) for the treatment of persistent facial erythema. In our experience, satisfactory improvement of persistent facial erythema with these therapies is uncommon (see <a class="local">'Pharmacologic therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate disease </strong>– For patients with mild to moderate rosacea manifesting with papules and pustules, we suggest treatment with topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, or topical <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>) (see <a class="local">'Mild to moderate disease'</a> above). The lower cost of metronidazole 0.75% gel (the least expensive formulation of metronidazole) compared with azelaic acid and ivermectin favors the initial use of metronidazole. We also favor metronidazole or ivermectin in patients who present with significant facial sensitivity, due to the fairly frequent occurrence of irritation early in the course of therapy with azelaic acid. Topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and topical sodium <a class="drug drug_general" data-topicid="9958" href="/z/d/drug information/9958.html" rel="external">sulfacetamide</a> are alternative topical therapies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe disease and milder disease that fails to respond to topical therapy </strong>– For patients who present with numerous papules or pustules or who have milder disease that fails to improve with topical agents, we suggest treatment with oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> for 4 to 12 weeks (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Improvement may be maintained with topical agents or subantimicrobial doxycycline. (See <a class="local">'Moderate to severe disease'</a> above and <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease </strong>– Patients with refractory papules or pustules may benefit from treatment with oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular involvement </strong>– Ocular involvement in rosacea can result in damage to the ocular tissues. Patients with signs or symptoms of ocular involvement should be referred to an ophthalmologist for further evaluation. (See <a class="local">'Ocular manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children </strong>– Childhood rosacea is managed similarly to rosacea in adults. However, the use of oral tetracyclines should be <strong>avoided </strong>in children under the age of nine. (See <a class="local">'Pediatric rosacea'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176:465.</a></li><li><a class="nounderline abstract_t">Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol 2020; 182:1269.</a></li><li><a class="nounderline abstract_t">Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis 2009; 84:97.</a></li><li><a class="nounderline abstract_t">Wilkin J. A role for vascular pathogenic mechanisms in rosacea: implications for patient care. Cutis 2008; 82:100.</a></li><li><a class="nounderline abstract_t">Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004; 50:266.</a></li><li><a class="nounderline abstract_t">Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163:719.</a></li><li><a class="nounderline abstract_t">Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51:327.</a></li><li class="breakAll">www.rosacea.org/rr/2002/summer/article_3.php (Accessed on December 28, 2010).</li><li><a class="nounderline abstract_t">Guarrera M, Parodi A, Cipriani C, et al. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982; 272:311.</a></li><li><a class="nounderline abstract_t">Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119:211.</a></li><li><a class="nounderline abstract_t">Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53:881.</a></li><li><a class="nounderline abstract_t">Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20:202.</a></li><li><a class="nounderline abstract_t">Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17:946.</a></li><li><a class="nounderline abstract_t">Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; :CD004923.</a></li><li><a class="nounderline abstract_t">Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol 2011; 147:1258.</a></li><li><a class="nounderline abstract_t">Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker. J Am Acad Dermatol 2012; 67:491.</a></li><li><a class="nounderline abstract_t">Taub AF, Devita EC. Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency. J Clin Aesthet Dermatol 2008; 1:37.</a></li><li><a class="nounderline abstract_t">Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol 2006; 5:6.</a></li><li><a class="nounderline abstract_t">Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias. J Cosmet Laser Ther 2011; 13:216.</a></li><li><a class="nounderline abstract_t">Goldberg DJ. Lasers and light sources for rosacea. Cutis 2005; 75:22.</a></li><li><a class="nounderline abstract_t">Wilkin JK. Use of topical products for maintaining remission in rosacea. Arch Dermatol 1999; 135:79.</a></li><li><a class="nounderline abstract_t">Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150:1136.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study. Cutis 2009; 84:72.</a></li><li><a class="nounderline abstract_t">Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat 2007; 18:158.</a></li><li><a class="nounderline abstract_t">Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg 2001; 20:209.</a></li><li><a class="nounderline abstract_t">Draelos ZD. Facial hygiene and comprehensive management of rosacea. Cutis 2004; 73:183.</a></li><li><a class="nounderline abstract_t">Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51:499.</a></li><li><a class="nounderline abstract_t">Nichols K, Desai N, Lebwohl MG. Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 1998; 61:344.</a></li><li><a class="nounderline abstract_t">Draelos ZD. Colored facial cosmetics. Dermatol Clin 2000; 18:621.</a></li><li><a class="nounderline abstract_t">Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008; 159:628.</a></li><li><a class="nounderline abstract_t">Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003; 29:600.</a></li><li><a class="nounderline abstract_t">Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold. Dermatol Surg 2003; 29:681.</a></li><li><a class="nounderline abstract_t">Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004; 30:37.</a></li><li><a class="nounderline abstract_t">Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004; 51:592.</a></li><li><a class="nounderline abstract_t">Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci 2002; 17:26.</a></li><li><a class="nounderline abstract_t">Lonne-Rahm S, Nordlind K, Edström DW, et al. Laser treatment of rosacea: a pathoetiological study. Arch Dermatol 2004; 140:1345.</a></li><li><a class="nounderline abstract_t">Tan ST, Bialostocki A, Armstrong JR. Pulsed dye laser therapy for rosacea. Br J Plast Surg 2004; 57:303.</a></li><li><a class="nounderline abstract_t">Schroeter CA, Haaf-von Below S, Neumann HA. Effective treatment of rosacea using intense pulsed light systems. Dermatol Surg 2005; 31:1285.</a></li><li><a class="nounderline abstract_t">Maxwell EL, Ellis DA, Manis H. Acne rosacea: effectiveness of 532 nm laser on the cosmetic appearance of the skin. J Otolaryngol Head Neck Surg 2010; 39:292.</a></li><li><a class="nounderline abstract_t">Iyer S, Fitzpatrick RE. Long-pulsed dye laser treatment for facial telangiectasias and erythema: evaluation of a single purpuric pass versus multiple subpurpuric passes. Dermatol Surg 2005; 31:898.</a></li><li><a class="nounderline abstract_t">Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers? Dermatol Surg 2004; 30:163.</a></li><li><a class="nounderline abstract_t">Tanghetti E, Sherr EA, Sierra R, Mirkov M. The effects of pulse dye laser double-pass treatment intervals on depth of vessel coagulation. Lasers Surg Med 2006; 38:16.</a></li><li><a class="nounderline abstract_t">Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 2009; 35:920.</a></li><li><a class="nounderline abstract_t">Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 2008; 40:233.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 2019; 181:65.</a></li><li><a class="nounderline abstract_t">Nielsen PG. A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109:63.</a></li><li><a class="nounderline abstract_t">Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48:836.</a></li><li><a class="nounderline abstract_t">Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40:961.</a></li><li><a class="nounderline abstract_t">Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32:65.</a></li><li><a class="nounderline abstract_t">Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol 2004; 43:381.</a></li><li><a class="nounderline abstract_t">Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78:649.</a></li><li><a class="nounderline abstract_t">Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43:151.</a></li><li><a class="nounderline abstract_t">Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis 2010; 86:7.</a></li><li><a class="nounderline abstract_t">Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36:942.</a></li><li><a class="nounderline abstract_t">Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166:633.</a></li><li><a class="nounderline abstract_t">Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12:650.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204708lbl.pdf (Accessed on August 27, 2013).</li><li><a class="nounderline abstract_t">Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 2015; 29:2405.</a></li><li><a class="nounderline abstract_t">Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014; 13:56.</a></li><li><a class="nounderline abstract_t">Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol 2014; 70:e37.</a></li><li><a class="nounderline abstract_t">Ilkovitch D, Pomerantz RG. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol 2014; 70:e109.</a></li><li><a class="nounderline abstract_t">Gillihan R, Nguyen T, Fischer R, et al. Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction. JAMA Dermatol 2015; 151:1136.</a></li><li><a class="nounderline abstract_t">Docherty JR, Steinhoff M, Lorton D, et al. Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy. Adv Ther 2016; 33:1885.</a></li><li><a class="nounderline abstract_t">Gold LS, Papp K, Lynde C, et al. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. J Drugs Dermatol 2017; 16:909.</a></li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf (Accessed on March 24, 2017).</li><li><a class="nounderline abstract_t">Kircik LH, DuBois J, Draelos ZD, et al. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. J Drugs Dermatol 2018; 17:97.</a></li><li><a class="nounderline abstract_t">Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. J Am Acad Dermatol 2018; 78:1156.</a></li><li><a class="nounderline abstract_t">Gold MH, Lebwohl M, Biesman BS, et al. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. J Am Acad Dermatol 2018; 79:e57.</a></li><li><a class="nounderline abstract_t">Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994; 130:319.</a></li><li><a class="nounderline abstract_t">Vienne MP, Ochando N, Borrel MT, et al. Retinaldehyde alleviates rosacea. Dermatology 1999; 199 Suppl 1:53.</a></li><li><a class="nounderline abstract_t">Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 2006; 5:227.</a></li><li><a class="nounderline abstract_t">Thompson BJ, Furniss M, Zhao W, et al. An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study. JAMA Dermatol 2014; 150:1013.</a></li><li><a class="nounderline abstract_t">Bageorgou F, Vasalou V, Tzanetakou V, Kontochristopoulos G. The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. J Cosmet Dermatol 2019; 18:563.</a></li><li><a class="nounderline abstract_t">Park JY, Ahn MK, Cho EB, et al. Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study. Dermatol Surg 2018; 44:1209.</a></li><li><a class="nounderline abstract_t">Schlessinger J, Lupin M, McDaniel D, George R. Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea. J Drugs Dermatol 2019; 18:522.</a></li><li><a class="nounderline abstract_t">Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol 2009; 23:239.</a></li><li><a class="nounderline abstract_t">Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50:107.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2015; :CD003262.</a></li><li><a class="nounderline abstract_t">Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 2001; 18:237.</a></li><li><a class="nounderline abstract_t">Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 2001; 45:723.</a></li><li><a class="nounderline abstract_t">Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006; 5:317.</a></li><li><a class="nounderline abstract_t">Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol 1987; 123:609.</a></li><li><a class="nounderline abstract_t">Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998; 61:44.</a></li><li><a class="nounderline abstract_t">Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 2007; 79:73.</a></li><li><a class="nounderline abstract_t">Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003; 139:1444.</a></li><li><a class="nounderline abstract_t">Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134:679.</a></li><li><a class="nounderline abstract_t">Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69:570.</a></li><li><a class="nounderline abstract_t">Mastrofrancesco A, Ottaviani M, Aspite N, et al. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol 2010; 19:813.</a></li><li><a class="nounderline abstract_t">Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991; 283:162.</a></li><li><a class="nounderline abstract_t">Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999; 79:456.</a></li><li><a class="nounderline abstract_t">Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 2008; 7:541.</a></li><li><a class="nounderline abstract_t">Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis 2007; 79:317.</a></li><li><a class="nounderline abstract_t">Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol 2005; 4:727.</a></li><li><a class="nounderline abstract_t">Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006; 77:3.</a></li><li><a class="nounderline abstract_t">Mostafa FF, El Harras MA, Gomaa SM, et al. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol 2009; 23:22.</a></li><li class="breakAll">Soolantra - ivermectin cream. US Food &amp; Drug Administration (FDA) approved product information. Revised December, 2014. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov (accessed Januray 5, 2015)).</li><li><a class="nounderline abstract_t">Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13:316.</a></li><li><a class="nounderline abstract_t">Stein Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014; 13:1380.</a></li><li><a class="nounderline abstract_t">Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther 2019; 32:e13093.</a></li><li><a class="nounderline abstract_t">Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015; 172:1103.</a></li><li><a class="nounderline abstract_t">Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol 2016; 30:829.</a></li><li><a class="nounderline abstract_t">Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol 2020; 82:1166.</a></li><li><a class="nounderline abstract_t">Stein Gold L, Del Rosso JQ, Kircik L, et al. Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea. J Clin Aesthet Dermatol 2020; 13:44.</a></li><li><a class="nounderline abstract_t">Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat 1997; 8:79.</a></li><li><a class="nounderline abstract_t">Davis GF, Glazer SD, Medansky RS. Successful treatment of rosacea with a novel formulation of sodium sulfacetamide 10% and sulfur 5% (Novacet,) topical lotion. J Geriatr Dermatol 1994; 2:140.</a></li><li><a class="nounderline abstract_t">Torok HM, Webster G, Dunlap FE, et al. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005; 75:357.</a></li><li><a class="nounderline abstract_t">Mills OH Jr, Kligman AM. Letter: Topically applied erythromycin in rosacea. Arch Dermatol 1976; 112:553.</a></li><li><a class="nounderline abstract_t">Altinyazar HC, Koca R, Tekin NS, Eştürk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005; 44:252.</a></li><li><a class="nounderline abstract_t">Chang AL, Alora-Palli M, Lima XT, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. J Drugs Dermatol 2012; 11:333.</a></li><li><a class="nounderline abstract_t">Koçak M, Yağli S, Vahapoğlu G, Ekşioğlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002; 205:265.</a></li><li><a class="nounderline abstract_t">Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156:728.</a></li><li><a class="nounderline abstract_t">Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008; 22:729.</a></li><li><a class="nounderline abstract_t">Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol 2010; 62:1050.</a></li><li><a class="nounderline abstract_t">Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22:287.</a></li><li><a class="nounderline abstract_t">Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13:975.</a></li><li><a class="nounderline abstract_t">Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007; 6:495.</a></li><li><a class="nounderline abstract_t">Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 2009; 23:876.</a></li><li><a class="nounderline abstract_t">Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; 2:1049.</a></li><li><a class="nounderline abstract_t">Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47:284.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56:791.</a></li><li><a class="nounderline abstract_t">Sanchez J, Somolinos AL, Almodóvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005; 53:791.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7:573.</a></li><li><a class="nounderline abstract_t">van der Linden MMD, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol 2017; 176:1465.</a></li><li><a class="nounderline abstract_t">Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6:641.</a></li><li><a class="nounderline abstract_t">Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol 2020; 82:336.</a></li><li><a class="nounderline abstract_t">Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102:443.</a></li><li><a class="nounderline abstract_t">Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25:660.</a></li><li><a class="nounderline abstract_t">Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134:884.</a></li><li><a class="nounderline abstract_t">Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8:505.</a></li><li><a class="nounderline abstract_t">Sbidian E, Vicaut É, Chidiack H, et al. A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea. J Invest Dermatol 2016; 136:1124.</a></li><li><a class="nounderline abstract_t">Turjanmaa K, Reunala T. Isotretinoin treatment of rosacea. Acta Derm Venereol 1987; 67:89.</a></li><li><a class="nounderline abstract_t">Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol 2003; 2:254.</a></li><li><a class="nounderline abstract_t">Lowe NJ, Behr KL, Fitzpatrick R, et al. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 1991; 17:522.</a></li><li><a class="nounderline abstract_t">Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. J Eur Acad Dermatol Venereol 2009; 23:200.</a></li><li><a class="nounderline abstract_t">Berg M, Edström DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. Lasers Surg Med 2004; 34:266.</a></li><li><a class="nounderline abstract_t">Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 2007; 21:1199.</a></li><li><a class="nounderline abstract_t">Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology 2005; 211:135.</a></li><li><a class="nounderline abstract_t">Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol 2004; 15:499.</a></li><li><a class="nounderline abstract_t">Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis 2001; 68:112.</a></li><li><a class="nounderline abstract_t">Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004; 137:138.</a></li><li><a class="nounderline abstract_t">Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996; 103:1880.</a></li><li><a class="nounderline abstract_t">Kligman AM. Ocular rosacea. Current concepts and therapy. Arch Dermatol 1997; 133:89.</a></li><li><a class="nounderline abstract_t">Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 2009; 23:544.</a></li><li><a class="nounderline abstract_t">Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26:651.</a></li><li><a class="nounderline abstract_t">Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol 2000; 42:468.</a></li><li><a class="nounderline abstract_t">Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982; 6:766.</a></li><li><a class="nounderline abstract_t">Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. Br J Dermatol 2009; 161:814.</a></li><li><a class="nounderline abstract_t">Tahery J, Zakaria R, Natt RS. Diode laser treatment of rhinophyma. Clin Otolaryngol 2010; 35:442.</a></li><li><a class="nounderline abstract_t">Apikian M, Goodman GJ, Roberts S. Management of mild to moderate rhinophyma with a 1,450-nm diode laser: report of five patients. Dermatol Surg 2007; 33:847.</a></li><li><a class="nounderline abstract_t">Kempiak SJ, Lee PW, Pelle MT. Rhinophyma treated with cryosurgery. Dermatol Surg 2009; 35:543.</a></li><li><a class="nounderline abstract_t">Sadick H, Goepel B, Bersch C, et al. Rhinophyma: diagnosis and treatment options for a disfiguring tumor of the nose. Ann Plast Surg 2008; 61:114.</a></li><li><a class="nounderline abstract_t">Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584.</a></li><li><a class="nounderline abstract_t">Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol 1991; 25:1038.</a></li><li><a class="nounderline abstract_t">Sánchez JL, Berlingeri-Ramos AC, Dueño DV. Granulomatous rosacea. Am J Dermatopathol 2008; 30:6.</a></li><li><a class="nounderline abstract_t">Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992; 9:22.</a></li><li><a class="nounderline abstract_t">Khokhar O, Khachemoune A. A case of granulomatous rosacea: sorting granulomatous rosacea from other granulomatous diseases that affect the face. Dermatol Online J 2004; 10:6.</a></li><li><a class="nounderline abstract_t">Schewach-Millet M, Shpiro D, Trau H. Granulomatous rosacea. J Am Acad Dermatol 1988; 18:1362.</a></li><li><a class="nounderline abstract_t">Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis 1990; 46:413.</a></li><li><a class="nounderline abstract_t">Krause MH, Torricelli R, Kündig T, et al. [Dapsone in granulomatous rosacea]. Hautarzt 1997; 48:246.</a></li><li><a class="nounderline abstract_t">Cunha PR, Rossi AB. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86:71.</a></li><li><a class="nounderline abstract_t">Gül U, Gönül M, Kiliç A, et al. A case of granulomatous rosacea successfully treated with pimecrolimus cream. J Dermatolog Treat 2008; 19:313.</a></li><li><a class="nounderline abstract_t">Lane JE, Khachemoune A. Use of intense pulsed light to treat refractory granulomatous rosacea. Dermatol Surg 2010; 36:571.</a></li><li><a class="nounderline abstract_t">Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther 2006; 19:196.</a></li><li><a class="nounderline abstract_t">Chamaillard M, Mortemousque B, Boralevi F, et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144:167.</a></li><li><a class="nounderline abstract_t">Gonser LI, Gonser CE, Deuter C, et al. Systemic therapy of ocular and cutaneous rosacea in children. J Eur Acad Dermatol Venereol 2017; 31:1732.</a></li><li><a class="nounderline abstract_t">Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale. Cutis 2008; 81:488.</a></li><li><a class="nounderline abstract_t">Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology 1994; 188:251.</a></li><li><a class="nounderline abstract_t">Strauss JS. Rosacea fulminans. J Eur Acad Dermatol Venereol 2001; 15:385.</a></li><li><a class="nounderline abstract_t">Ormond P, Rogers S. Case 3. Pyoderma faciale (PF) (rosacea fulminans). Clin Exp Dermatol 2003; 28:107.</a></li><li><a class="nounderline abstract_t">Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol 2001; 15:465.</a></li></ol></div><div id="topicVersionRevision">Topic 16632 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861741" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392722" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19746768" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Standard management options for rosacea, part 2: options according to subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18792539" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A role for vascular pathogenic mechanisms in rosacea: implications for patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726884" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Temperature regulates bacterial protein production: possible role in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20545683" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337973" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rosacea: I. Etiology, pathogenesis, and subtype classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337973" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rosacea: I. Etiology, pathogenesis, and subtype classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219630" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Flushing in rosacea: a possible mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6218789" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243148" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521641" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of nadolol on flushing reactions in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505547" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824841" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Non-hormonal interventions for hot flushes in women with a history of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768447" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890733" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselectiveβ-adrenergic blocker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21103309" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16485874" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21848421" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intense pulsed light for the treatment of rosacea and telangiectasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15810807" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lasers and light sources for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9923787" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of topical products for maintaining remission in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214900" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19746764" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594677" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cosmetics in acne and rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15074346" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Facial hygiene and comprehensive management of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389184" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rosacea: II. Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9640556" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effective sunscreen ingredients and cutaneous irritation in patients with rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11059370" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Colored facial cosmetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565174" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828690" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692924" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389196" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11845365" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Laser treatment of erythema and telangiectasia associated with rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545543" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Laser treatment of rosacea: a pathoetiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15145732" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulsed dye laser therapy for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16188180" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effective treatment of rosacea using intense pulsed light systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470675" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acne rosacea: effectiveness of 532 nm laser on the cosmetic appearance of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042933" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-pulsed dye laser treatment for facial telangiectasias and erythema: evaluation of a single purpuric pass versus multiple subpurpuric passes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756644" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444693" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effects of pulse dye laser double-pass treatment intervals on depth of vessel coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397667" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412227" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30585305" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6222756" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789172" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10365928" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425809" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of rosacea: topical clindamycin versus oral tetracycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117375" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4224811" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A clinical trial of tetracycline in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125511" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Therapeutic potential of azithromycin in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21229826" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466207" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clarithromycin versus doxycycline in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22050040" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839181" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839181" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416154" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385120" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24438976" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24742853" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Brimonidine effective but may lead to significant rebound erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083825" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27562835" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28915286" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28915286" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320594" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409914" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860043" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129410" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10473962" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Retinaldehyde alleviates rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17177744" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054629" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099833" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29746429" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31251544" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498336" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical efficacy of tacrolimus in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699377" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Tacrolimus effect on rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25919144" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Interventions for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841193" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Potential antioxidant mechanism of action for metronidazole: implications for rosacea management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606923" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16673797" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2953312" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Topical metronidazole therapy for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466083" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330626" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623704" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645635" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Topical metronidazole maintains remissions of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871720" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20545756" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867478" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598760" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18561584" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17500380" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302558" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16706244" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18705632" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Comparative study of some treatment modalities of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18705632" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Comparative study of some treatment modalities of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24595578" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607706" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31579993" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25228137" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691278" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004648" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33282103" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Successful treatment of rosacea with a novel formulation of sodium sulfacetamide 10% and sulfur 5% (Novacet,) topical lotion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047874" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/131516" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Letter: Topically applied erythromycin in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807740" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Adapalene vs. metronidazole gel for the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395584" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399675" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493072" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328059" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466178" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Rosaceiform dermatitis associated with topical tacrolimus treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786821" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Tetracycline actions relevant to rosacea treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17676051" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679183" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508315" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Current topical and systemic approaches to treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4106909" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289334" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17367893" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243127" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18561589" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797396" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17668530" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31150711" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6446314" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2948928" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Treatment of rosacea with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9681365" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20337772" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26854486" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436425" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Isotretinoin treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12848109" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Treatment of rosacea with intense pulsed light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1828257" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452529" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022255" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894705" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Photodynamic therapy in a series of rosacea patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088160" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Photodynamic therapy in the treatment of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523195" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Ocular rosacea: an update on pathogenesis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11534911" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : The ocular manifestations of rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700657" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Ocular rosacea in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942885" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The efficacy of topical metronidazole in the treatment of ocular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006377" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Ocular rosacea. Current concepts and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250326" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19551353" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Efficacy of topical cyclosporine for the treatment of ocular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688718" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : The clinicopathologic spectrum of rhinophyma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6461680" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Action of isotretinoin in acne rosacea and gram-negative folliculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624541" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Carbon dioxide laser treatment of rhinophyma: a review of 124 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21108762" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Diode laser treatment of rhinophyma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598853" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Management of mild to moderate rhinophyma with a 1,450-nm diode laser: report of five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19292842" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Rhinophyma treated with cryosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580161" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Rhinophyma: diagnosis and treatment options for a disfiguring tumor of the nose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907512" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1839796" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : A clinical and histopathologic study of granulomatous rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18212536" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Granulomatous rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1533454" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Childhood rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347488" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : A case of granulomatous rosacea: sorting granulomatous rosacea from other granulomatous diseases that affect the face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2968381" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Granulomatous rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2148143" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9206712" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : [Dapsone in granulomatous rosacea].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585999" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Pimecrolimus cream 1% is effective in a case of granulomatous rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608739" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : A case of granulomatous rosacea successfully treated with pimecrolimus cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402938" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Use of intense pulsed light to treat refractory granulomatous rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004995" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Pediatric rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283173" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Cutaneous and ocular signs of childhood rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28621909" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Systemic therapy of ocular and cutaneous rosacea in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18666391" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Pyoderma faciale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193395" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Diagnosis and treatment of rosacea fulminans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11763373" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Rosacea fulminans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12558651" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Case 3. Pyoderma faciale (PF) (rosacea fulminans).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11763393" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Dapsone in rosacea fulminans.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
